Global Focal segmental glomerulosclerosis (FSGS) Market: Snapshot

Focal segmental glomerulosclerosis (FSGS), a rare health condition, afflicts around 210,200 patients worldwide and about 14,000 to 16,000 new cases are diagnosed annually. The rising numbers along the considerable untapped opportunities in the market on account of a limited number of pipeline products are serving to boost it. Continued thrust by non-government organizations to increase awareness about the rare disease and increasing allocation towards research on rare diseases too are proving beneficial for the market for focal segmental glomerulosclerosis.

Rising at a 8.0% CAGR from 2017 to 2025, the global focal segmental glomerulosclerosis (FSGS) market will likely become worth US$15.83 bn by 2025-end fromUS$7.82 bn in 2016, finds a report by Transparency Market Research.

focal segmental glomerulosclerosis market

Primary Focal Segmental Glomerulosclerosis Garners Greater Market Share due to Awareness About it

Depending upon the disease type, the market can be bifurcated into primary focal segmental glomerulosclerosis and secondary focal segmental glomerulosclerosis. Of the two, the segment of primary focal segmental glomerulosclerosis held a mammoth 79.8% share in the market in 2016. Also known as primary idiopathic/genetic focal segmental glomerulosclerosis, primary focal segmental glomerulosclerosis is a kind of the focal segmental glomerulosclerosis disease without a known or obvious cause. Growing awareness about the disease and its management is at the forefront of driving growth in the segment.

Depending upon the management of the disease, the global market for focal segmental glomerulosclerosis (FSGS) can again be split broadly into diagnosis and treatment. The segment of diagnosis can be further divided into creatine test, kidney biopsy, etc. The segment of treatment again can be further divided into drug therapy, kidney transplant, and dialysis. At present, the treatment segment contributes to most of the revenue in the market for focal segmental glomerulosclerosis (FSGS). This is because of the massive unmet requirements in the market. A promising pipeline of novel molecules and their approval will continue boosting the segment in the next couple of years.

Considerable Penetration of Treatment Drives U.S. Market to Fore

Geographically, North America accounts for a leading share in the market for focal segmental glomerulosclerosis because of the presence of a properly structured health care industry and availability of reimbursement policies with wider coverage. The U.S. is mainly serving to drive the market in North America due to the greater uptake of advanced and high-cost drug therapies, considerable penetration of treatment, and helpful reimbursement policies. Another factor stoking market growth in the U.S. is the classification of focal segmental glomerulosclerosis (FSGS) drugs under orphan disease drugs categories – companies involved in the production and clinical trials of drugs for orphan diseases receive exemption from payment of new drug application fee, provision of tax credits on clinical research, waivers for post-approval annual establishment and product fees, and exclusive marketing rights up to a period of seven years.

Europe trails North America in terms of market share. In 2016, the segment accounted for a share of 25.5%. Vis-à-vis growth rate, Asia Pacific is expected to outshine all other regions. The market in the region is being powered primarily by China which in turn is being propelled by the increasing diagnosis rate of focal segmental glomerulosclerosis, stupendous growth in the healthcare industry, and availability of drugs and dialysis at a lower price.

Some of the key participants in the global market for focal segmental glomerulosclerosis (FSGS) are Variant Pharmaceuticals, Inc., GlaxoSmithKline plc., Novartis AG, ChemoCentryx, Inc., Retrophin, Inc., AbbVie, Inc., AstraZeneca plc., Pfizer, Inc., Sanofi S.A, and Teva Pharmaceutical Industries Ltd.

Participation of Interprofessional Team Improves Patient Care in Focal Segmental Glomerulosclerosis (FSGS) Market

Focal segmental glomerular sclerosis (FSGS) is associated with podocyte injury and is a major cause of nephrotic syndrome, affecting adults and children. It is most frequently associated with kidney diseases, including end-of-life disease. The prevalence of FSGS, relative to other glomerular disease diagnoses, is increasing. It has a high incidence of 7 per 1 million with a prevalence as high as 4.0% according to some estimates. Advances made in pathogenesis of focal segmental glomerular sclerosis (FSGS) have pointed its role in full-blown nephrotic syndrome in children, propelling the need for research in the focal segmental glomerular sclerosis (FSGS) market. Numerous etiologies drive focal segmental glomerulosclerosis (FSGS). Growing awareness about prevalence of kidney disease drive prospects in the FSGS market. Given the high morbidity in patient populations, notable advances made in genetic testing, lab testing, and kidney biopsies. New assessment approaches in renal histology are boosting focal segmental glomerulosclerosis (FSGS) market. Growing cases of end-stage renal disease (ESRD) attributed to FSGS in developed and emerging nations present alarming scenario. The role of interprofessional teams in improving patient care is thus increasing, and will open new vistas of growth for industry players in the market.

The massive severity of the Covid-19 pandemic and its subsequent outbreaks have led policy makers, regulators, and industry players, and even the common populace to come forward join hands and fight against the humanitarian crisis. The collaborations and engagements across the value chain have thus paved way to new healthcare models, business and operating models for the economy, and new ways of working. The still-emerging pandemic due to new variants of Sars-CoV-2 has recently created a panic in some parts of Asia. Nevertheless, global commitment to combat the mortality and morbidity has improved the scenario in recent weeks. The needs of the pandemic has also spurred the demand for new production of essential goods and industrial chemicals, thereby offering opportunities masked in challenges. These factors are also likely to shape the contours of the focal segmental glomerular sclerosis (FSGS) market.

Global Focal Segmental Glomerulosclerosis (FSGS) Market: Overview

This report on focal segmental glomerulosclerosis (FSGS) market studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacturing and commercialization of diagnostic and therapeutic products for focal segmental glomerulosclerosis (FSGS) as well as new entrants planning to enter this market. This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments considered in the scope of the study. This section also provides the overall information and data analysis of the global focal segmental glomerulosclerosis (FSGS) market with respect to the leading market segments based on disease type, disease management and geographies.

The market overview section of the report explores the market dynamics such as drivers, restraints, and opportunities that currently have a strong impact on the focal segmental glomerulosclerosis (FSGS) market and could influence the market in the near future. Market attractiveness analysis has been provided in the market overview section in order to explain the intensity of competition in the market across different geographies. The competitive scenario among different market players is evaluated through market share analysis in the competitive landscape section of the report. All these factors would help market players to take strategic decisions in order to strengthen their positions and expand their shares in the global focal segmental glomerulosclerosis (FSGS) market.

Global Focal Segmental Glomerulosclerosis (FSGS) Market: Segmentation

Based on disease type, the focal segmental glomerulosclerosis (FSGS) market has been majorly segmented into primary focal segmental glomerulosclerosis and secondary focal segmental glomerulosclerosis. In terms of disease management, the focal segmental glomerulosclerosis (FSGS) market has been broadly classified into diagnosis and treatment. Diagnosis includes segments such as kidney biopsy, creatine test, and others. Treatment includes segments such as drug therapy, dialysis, and kidney transplant.

Each of the market segments have been extensively analyzed based on the market related factors such as incidence and prevalence of focal segmental glomerulosclerosis (FSGS), available treatments, and pipeline products. Moreover, historical year-on-year growth have been taken into consideration while estimating the market size. The market size and forecast in terms of US$ million for each segment has been provided for the period from 2015 to 2025. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2017 to 2025, considering 2016 as the base year.

Geographically, focal segmental glomerulosclerosis (FSGS) market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market size and forecast for each of these regions has been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year. The report also provides market size and forecast for major countries in the respective regions. A detailed qualitative analysis of factors responsible for driving and restraining the market growth and future opportunities has been provided in the market overview section. This section of the report also provides market attractiveness analysis, porter’s five forces analysis, and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global focal segmental glomerulosclerosis (FSGS) market.

Global Focal Segmental Glomerulosclerosis (FSGS) Market: Competitive Dynamics

The key players operating in the focal segmental glomerulosclerosis (FSGS) market are Variant Pharmaceuticals, Inc., ChemoCentryx, Inc., Retrophin, Inc., AbbVie, Inc., Novartis AG, Pfizer, Inc., AstraZeneca plc., Sanofi S.A, GlaxoSmithKline plc. and Teva Pharmaceutical Industries Ltd. The global focal segmental glomerulosclerosis (FSGS) market is expected to undergo change after the successful pipeline product launch during the forecast period.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

The global focal segmental glomerulosclerosis (FSGS) market is segmented as follows:

Disease Type

  • Primary Focal Segmental Glomerulosclerosis
  • Secondary Focal Segmental Glomerulosclerosis

Disease Management

  • Diagnosis
    • Kidney Biopsy
    • Creatine Test
    • Others
  • Treatment
    • Drug Therapy
    • Dialysis
    • Kidney Transplant

Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • U.K.
    • Rest of Europe
  • Asia Pacific
    • India
    • Japan
    • China
    • Australia & New Zealand
    • Rest of Asia
  • Latin America (LATAM)
    • Brazil
    • Mexico
    • Rest of LATAM
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

With a robust experience in creating exceptional market reports, Transparency Market Research has emerged as one of the trusted market research companies among a large number of stakeholders and CXOs. Every report at Transparency Market Research goes through rigorous research activity in every aspect. The researchers at TMR keep a close watch on the market and extract beneficial growth-boosting points. These points help the stakeholders to strategize their business plans accordingly.

TMR researchers conduct exhaustive qualitative and quantitative research. This research involves taking inputs from the experts in the market, focused attention on recent developments, and others. This method of research makes TMR stand out from other market research firms.

Here's how Transparency Market Research helps the stakeholders and CXOs through the reports:

Inculcation and Evaluation of Strategic Collaborations: The TMR researchers analyze recent strategic activities like mergers, acquisitions, partnerships, collaborations, and joint ventures. All the information is compiled and included in the report.

Perfect Market Size Estimations: The report analyzes the demographics, growth potential, and capability of the market through the forecast period. This factor leads to the estimation of the market size and also provides an outline about how the market will retrieve growth during the assessment period.

Investment Research: The report focuses on the ongoing and upcoming investment opportunities across a particular market. These developments make the stakeholders aware of the current investment scenario across the market.

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

1. Preface 
     1.1. Report Scope and Market Segmentation 
     1.2. Research Highlights

2. Assumptions and Research Methodology 
     2.1. Assumptions
     2.2. Research Methodology

3. Executive Summary
     3.1. Global Focal Segmental Glomerulosclerosis Market Snapshot

4. Market Overview
     4.1. Product Overview
     4.2. Key Industry Events
     4.3. Global Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, 2015–2025
     4.4. Market Opportunity Map
     4.5. Global Focal Segmental Glomerulosclerosis Market Outlook
     4.6. Overview of Clinical Trials
     4.7. Global Focal Segmental Glomerulosclerosis Prevalence Scenario-2016, by Region

5. Market Dynamics
     5.1. Drivers and Restraints Snapshot Analysis 
     5.2. Drivers
            5.2.1. Increasing burden of focal segmental glomerulosclerosis (FSGS)
            5.2.2. Untapped market opportunities with a limited number of pipeline products
            5.2.3. Efforts by non-government organizations to raise awareness
            5.2.4. Strong focus on R&D activities for developing new therapies and drugs
            5.2.5. Rise in funding for research on rare diseases
     5.3. Restraints
            5.3.1. High cost of kidney dialysis and kidney transplant treatments
            5.3.2. Difficulty in recruitment for clinical trials
            5.3.3. Non-availability of approved drugs and dearth of trained medical professionals
     5.4. Opportunities
            5.4.1. Promising pipeline of novel molecules and their approval
            5.4.2. Unmet needs for management of focal segmental glomerulosclerosis (FSGS)

6. Global Focal Segmental Glomerulosclerosis Market Analysis, by Disease Type
     6.1. Introduction 
     6.2. Key Findings
     6.3. Global Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type
     6.4. Global Focal Segmental Glomerulosclerosis Market Forecast, by Disease Type
            6.4.1. Primary Focal Segmental Glomerulosclerosis
            6.4.2. Secondary Focal Segmental Glomerulosclerosis
     6.5. Global Focal Segmental Glomerulosclerosis Market Analysis, by Disease Type
     6.6. Global Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Type
     6.7. Key Trends

7. Global Focal Segmental Glomerulosclerosis Market Analysis, by Disease Management
     7.1. Introduction 
     7.2. Key Findings
     7.3. Global Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management
     7.4. Global Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management
            7.4.1. Diagnosis
            7.4.2. Treatment
     7.5. Global Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management – Diagnosis
            7.5.1. Kidney Biopsy
            7.5.2. Creatine Test
            7.5.3. Others
     7.6. Global Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management – Treatment
            7.6.1. Drug Therapy
            7.6.2. Dialysis
            7.6.3. Kidney Transplant
     7.7. Global Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Management 
     7.8. Key Trends

8. Global Focal Segmental Glomerulosclerosis Market Analysis, by Region
     8.1. Global Market Scenario, by Country
     8.2. Global Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Region 
     8.3. Global Focal Segmental Glomerulosclerosis Market Forecast, by Region
            8.3.1.  North America
            8.3.2. Europe
            8.3.3. Asia Pacific
            8.3.4. Latin America
            8.3.5. Middle East & Africa
     8.4. Global Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Region 
     8.5. Regulatory Scenario by Region/Key Countries

9. North America Focal Segmental Glomerulosclerosis Market Analysis
     9.1. Key Findings
     9.2. North America Focal Segmental Glomerulosclerosis Market Overview
     9.3. North America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country
     9.4. North America Focal Segmental Glomerulosclerosis Market Forecast, by Country
            9.4.1. U.S.
            9.4.2. Canada
     9.5. North America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type
     9.6. North America Focal Segmental Glomerulosclerosis Market Forecast, by Disease Type
     9.7. North America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management
     9.8. North America Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management
     9.9. North America Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management - Diagnosis
     9.10. North America Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management - Treatment
     9.11. North America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis

10. Europe Focal Segmental Glomerulosclerosis Market Analysis
     10.1. Key Findings
     10.2. Europe Focal Segmental Glomerulosclerosis Market Overview
     10.3. Europe Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country
     10.4. Europe Focal Segmental Glomerulosclerosis Market Forecast, by Country
            10.4.1. Germany
            10.4.2. U.K.
            10.4.3. Spain 
            10.4.4. France 
            10.4.5. Russia 
            10.4.6. Poland 
            10.4.7. Rest of Europe
     10.5. Europe Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type
     10.6. Europe Focal Segmental Glomerulosclerosis Market Forecast, by Disease Type
     10.7. Europe Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management
     10.8. Europe Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management
     10.9. Europe Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management – Diagnosis
     10.10. Europe Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management – Treatment
     10.11. Europe Focal Segmental Glomerulosclerosis Market Attractiveness Analysis

11. Asia Pacific Focal Segmental Glomerulosclerosis Market Analysis
     11.1. Key Findings
     11.2. Asia Pacific Focal Segmental Glomerulosclerosis Market Overview
     11.3. Asia Pacific Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country
     11.4. Asia Pacific Focal Segmental Glomerulosclerosis Market Forecast, by Country
            11.4.1. India 
            11.4.2. Japan 
            11.4.3. China 
            11.4.4. Australia & New Zealand
            11.4.5. Rest of Asia Pacific
     11.5. Asia Pacific Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type
     11.6. Asia Pacific Focal Segmental Glomerulosclerosis Market Forecast, by Disease Type
     11.7. Asia Pacific Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management
     11.8. Asia Pacific Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management
     11.9. Asia Pacific Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management – Diagnosis
     11.10. Asia Pacific Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management – Treatment
     11.11. Asia Pacific Focal Segmental Glomerulosclerosis Market Attractiveness Analysis

12. Latin America Focal Segmental Glomerulosclerosis Market Analysis
     12.1. Key Findings
     12.2. Latin America Focal Segmental Glomerulosclerosis Market Overview
     12.3. Latin America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country
     12.4. Latin America Focal Segmental Glomerulosclerosis Market Forecast, by Country
            12.4.1. Brazil
            12.4.2. Mexico 
            12.4.3. Rest of Latin America
     12.5. Latin America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type
     12.6. Latin America Focal Segmental Glomerulosclerosis Market Forecast, by Disease Type
     12.7. Latin America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management
     12.8. Latin America Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management
     12.9. Latin America Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management – Diagnosis
     12.10. Latin America Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management – Treatment
     12.11. Latin America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis

13. Middle East & Africa Focal Segmental Glomerulosclerosis Market Analysis
     13.1. Key Findings
     13.2. Middle East & Africa Focal Segmental Glomerulosclerosis Market Overview
     13.3. Middle East & Africa Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country
     13.4. Middle East & Africa Focal Segmental Glomerulosclerosis Market Forecast, by Country
            13.4.1. GCC Countries
            13.4.2. South Africa 
            13.4.3. Rest of Middle East & Africa
     13.5. Middle East & Africa Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type
     13.6. Middle East & Africa Focal Segmental Glomerulosclerosis Market Forecast, by Disease Type
     13.7. Middle East & Africa Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management
     13.8. Middle East & Africa Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management
     13.9. Middle East & Africa Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management – Diagnosis
     13.10. Middle East & Africa Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management – Treatment
     13.11. Middle East & Africa Focal Segmental Glomerulosclerosis Market Attractiveness Analysis

14. Competition Landscape
     14.1. Competition Matrix 
     14.2. Company Profiles
            14.2.1. Variant Pharmaceuticals, Inc.
                      14.2.1.1. Company Details
                      14.2.1.2. Business Overview
                      14.2.1.3. Strategic Overview
                      14.2.1.4. SWOT Analysis
            14.2.2. ChemoCentryx, Inc. 
                      14.2.2.1. Company Details
                      14.2.2.2. Business Overview
                      14.2.2.3. Strategic Overview
                      14.2.2.4. SWOT Analysis
            14.2.3. Retrophin, Inc. 
                      14.2.3.1. Company Details
                      14.2.3.2. Business Overview
                      14.2.3.3. Strategic Overview
                      14.2.3.4. SWOT Analysis
            14.2.4. AbbVie, Inc.
                      14.2.4.1. Company Details
                      14.2.4.2. Business Overview
                      14.2.4.3. Financial Overview
                      14.2.4.4. Strategic Overview
                      14.2.4.5. SWOT Analysis
            14.2.5. Novartis AG 
                      14.2.5.1. Company Details
                      14.2.5.2. Business Overview
                      14.2.5.3. Financial Overview
                      14.2.5.4. Strategic Overview
                      14.2.5.5. SWOT Analysis
            14.2.6. Pfizer, Inc. 
                      14.2.6.1. Company Details
                      14.2.6.2. Business Overview
                      14.2.6.3. Financial Overview
                      14.2.6.4. Strategic Overview
                      14.2.6.5. SWOT Analysis
            14.2.7. AstraZeneca plc. 
                      14.2.7.1. Company Details
                      14.2.7.2. Business Overview
                      14.2.7.3. Financial Overview
                      14.2.7.4. Strategic Overview
                      14.2.7.5. SWOT Analysis
            14.2.8. Sanofi S.A.  
                      14.2.8.1. Company Details
                      14.2.8.2. Business Overview
                      14.2.8.3. Financial Overview
                      14.2.8.4. Strategic Overview
                      14.2.8.5. SWOT Analysis
            14.2.9. GlaxoSmithKline plc. 
                      14.2.9.1. Company Details
                      14.2.9.2. Business Overview
                      14.2.9.3. Financial Overview
                      14.2.9.4. Strategic Overview
                      14.2.9.5. SWOT Analysis
            14.2.10. Teva Pharmaceutical Industries Ltd. 
                      14.2.10.1. Company Details
                      14.2.10.2. Business Overview
                      14.2.10.3. Financial Overview
                      14.2.10.4. Strategic Overview
                      14.2.10.5. SWOT Analysis

List of Tables

TABLE 1 Global Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2015–2025
TABLE 2 Global Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management, 2015–2025
TABLE 3 Global Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management - Diagnosis, 2015–2025
TABLE 4 Global Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management - Treatment, 2015–2025
TABLE 5 Global Focal Segmental Glomerulosclerosis Market Revenue (US$ Mn) Forecast, by Region, 2015–2025
TABLE 6 North America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Country, 2015–2025
TABLE 7 North America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2015–2025
TABLE 8 North America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management, 2015–2025
TABLE 9 North America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease
TABLE 10 North America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management - Treatment, 2015–2025
TABLE 11 Europe Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
TABLE 12 Europe Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2015–2025
TABLE 13 Europe Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management,
TABLE 14 Europe Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management - Diagnosis, 2015–2025
TABLE 15 Europe Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management - Treatment, 2015–2025
TABLE 16 Asia Pacific Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
TABLE 17 Asia Pacific Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2015–2025
TABLE 18 Asia Pacific Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management, 2015–2025
TABLE 19 Asia Pacific Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management - Diagnosis, 2015–2025
TABLE 20 Asia Pacific Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management - Treatment, 2015–2025
TABLE 21 Latin America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
TABLE 22 Latin America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2015–2025
TABLE 23 Latin America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management, 2015–2025
TABLE 24 Latin America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management - Diagnosis, 2015–2025
TABLE 25 Latin America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management - Treatment, 2015–2025
TABLE 26 Middle East & Africa Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
TABLE 27 Middle East & Africa Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2015–2025
TABLE 28 Middle East & Africa Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management, 2015–2025
TABLE 29 Middle East & Africa Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management - Diagnosis, 2015–2025
TABLE 30 Middle East & Africa Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management - Treatment, 2015–2025

List of Figures

FIG. 1 Market Opportunity Map - By Disease Type, 2016 Revenue Share
FIG. 2 Market Opportunity Map - By Disease Management, 2016 Revenue Share
FIG. 3 Global Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, 2015–2025
FIG. 4 Market Value Share, by Disease Management - Diagnosis (2016)
FIG. 5 Market Value Share, by Disease Management - Treatment (2016)
FIG. 6 Market Value Share, by Disease Type (2016)
FIG. 7 Market Value Share, by Region (2016)
FIG. 8 Global Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type, 2016 and 2025
FIG. 9 Global Focal Segmental Glomerulosclerosis Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Primary Focal Segmental Glomerulosclerosis, 2015–2025
FIG. 10 Global Focal Segmental Glomerulosclerosis Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Secondary Focal Segmental Glomerulosclerosis, 2015–2025
FIG. 11 Global Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Type, 2015–2025
FIG. 12 Global Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management, 2016 and 2025
FIG. 13 Global Focal Segmental Glomerulosclerosis Market Value (US$ Mn) and Y-o-Y Growth, by Diagnosis, 2015–2025
FIG. 14 Global Focal Segmental Glomerulosclerosis Market Value (US$ Mn) and Y-o-Y Growth, by Treatment, 2015–2025
FIG. 15 Global Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Management, 2015–2025
FIG. 16 Global Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Region, 2016 and 2025
FIG. 17 Global Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Region, 2017–2025 
FIG. 18 North America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2015–2025
FIG. 19 North America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Country, 2017–2025
FIG. 20 North America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country, 2016 and 2025
FIG. 21 North America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type, 2016 and 2025
FIG. 22 North America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management, 2016 and 2025
FIG. 23 North America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management - Diagnosis, 2016 and 2025
FIG. 24 North America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management - Treatment, 2016 and 2025
FIG. 25 North America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Type, 2015–2025
FIG. 26 North America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Management, 2015–2025
FIG. 27 Europe Focal Segmental Glomerulosclerosis Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2015–2025
FIG. 28 Europe Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Country/Sub-region, 2017–2025
FIG. 29 Europe Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
FIG. 30 Europe Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type, 2016 and 2025
FIG. 31 Europe Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management, 2016 and 2025
FIG. 32 Europe Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management - Diagnosis, 2016 and 2025
FIG. 33 Europe Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management - Treatment, 2016 and 2025
FIG. 34 Europe Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Type, 2015–2025
FIG. 35 Europe Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Management, 2015–2025
FIG. 36 Asia Pacific Focal Segmental Glomerulosclerosis Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2015–2025
FIG. 37 Asia Pacific Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Country/Sub-region, 2017–2025
FIG. 38 Asia Pacific Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
FIG. 39 Asia Pacific Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type, 2016 and 2025
FIG. 40 Asia Pacific Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management, 2016 and 2025
FIG. 41 Asia Pacific Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management - Diagnosis, 2016 and 2025
FIG. 42 Asia Pacific Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management - Treatment, 2016 and 2025
FIG. 43 Asia Pacific Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Type, 2015–2025
FIG. 44 Asia Pacific Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Management, 2015–2025
FIG. 45 Latin America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2015–2025
FIG. 46 Latin America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Country/Sub-region, 2017–2025
FIG. 47 Latin America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
FIG. 48 Latin America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type, 2016 and 2025
FIG. 49 Latin America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management, 2016 and 2025
FIG. 50 Latin America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management - Diagnosis, 2016 and 2025
FIG. 51 Latin America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management - Treatment, 2016 and 2025
FIG. 52 Latin America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Type, 2015–2025
FIG. 53 Latin America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Management, 2015–2025
FIG. 54 Middle East & Africa Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015–2025
FIG. 55 Middle East & Africa Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Country/Sub-region, 2017–2025
FIG. 56 Middle East & Africa Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
FIG. 57 Middle East & Africa Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type, 2016 and 2025
FIG. 58 Middle East & Africa Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management, 2016 and 2025
FIG. 59 Middle East & Africa Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management - Diagnosis, 2016 and 2025
FIG. 60 Middle East & Africa Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management - Treatment, 2016 and 2025
FIG. 61 AbbVie, Inc. - Breakdown of Net Sales, by Region,2015
FIG. 62 AbbVie, Inc. Revenue (US$ Bn) & Y-o-Y Growth (%), 2012–2015
FIG. 63 Novartis AG Breakdown of Net Sales, by Region, 2016
FIG. 64 Novartis AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
FIG. 65 Pfizer, Inc. Breakdown of Net Sales, by Region, 2015
FIG. 66 Pfizer, Inc. Revenue (US$ Bn) & Y-o-Y Growth (%), 2012–2015
FIG. 67 AstraZeneca plc Breakdown of Net Sales, by Region, 2015
FIG. 68 AstraZeneca plc Revenue (US$ Bn) & Y-o-Y Growth (%), 2012–2015
FIG. 69 Sanofi S.A. Breakdown of Net Sales, by Region, 2015
FIG. 70 Sanofi S.A. Revenue (US$ Bn) & Y-o-Y Growth (%), 2012–2015
FIG. 71 GlaxoSmithKline plc. Breakdown of Net Sales, by Region,2015
FIG. 72 GlaxoSmithKline plc. Revenue (US$ Bn) & Y-o-Y Growth (%), 2012–2015
FIG. 73 Teva Pharmaceutical Industries Ltd. Breakdown of Net Sales, by Region, 2015
FIG. 74 Teva Pharmaceutical Industries Ltd. Revenue (US$ Bn) & Y-o-Y Growth (%), 2012–2015

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Focal Segmental Glomerulosclerosis Market